|
| Status |
Public on Oct 25, 2017 |
| Title |
AML 31 DAY 1 |
| Sample type |
RNA |
| |
|
| Source name |
Leukemic blasts
|
| Organism |
Homo sapiens |
| Characteristics |
cell type: Leukemic blasts
disease state: Acute myeloid leukemia
gender: M
age: 68
aml status: Secondary (CMF)
fab: M4
cd34: Pos
cd117: Pos
cytogenetics: Normal
|
| Extracted molecule |
total RNA |
| Extraction protocol |
RNA isolation was performed according to QIAgen's instructions in the RNeasy with DNase treatment protocol for the QIAcube.
|
| Label |
biotin
|
| Label protocol |
Biotinylated cRNA were prepared with the Illumina TotalPrep-96 RNA Amplification Kit from Thermo Fisher Scientific
|
| |
|
| Hybridization protocol |
Standard Illumina hybridization protocol
|
| Scan protocol |
Standard Illumina scanning protocol
|
| Data processing |
Data were quantile-normalised (http://www.molmine.com/magma/loading/illumina.html) using J-Express version 2012 (http://jexpress.bioinfo.no/site/)
|
| |
|
| Submission date |
Oct 24, 2017 |
| Last update date |
Oct 25, 2017 |
| Contact name |
Hakon Reikvam |
| E-mail(s) |
Hakon.Reikvam@uib.no
|
| Phone |
+4755585408
|
| Organization name |
University of Bergen
|
| Department |
Department of Clinical Science
|
| Street address |
Jonas Lies vei 65
|
| City |
Bergen |
| ZIP/Postal code |
5021 |
| Country |
Norway |
| |
|
| Platform ID |
GPL10558 |
| Series (1) |
| GSE106096 |
Disease-stabilizing treatment based on all-trans retinoic acid and valproic acid in acute myeloid leukemia |
|
